The relationship between TRIP13 and CRC patient survival was preliminarily analyzed, suggesting that TRIP13 is a potential biomarker for the treatment and prognosis of CRC, primarily early-stage CRC. This evidence concerns the gene TRIP13 and colorectal carcinoma.